Insider Transactions
| Date | Name | Title | Type | Shares Traded | Price Range |
|---|---|---|---|---|---|
| Apr 01, 2020 |
Chief Legal Officer
|
Chief Legal Officer | Open market or private sale of non-derivative or derivative security | 1,467 | $2.23 |
| Apr 01, 2020 |
EVP, COO & CCO
|
EVP, COO & CCO | Open market or private sale of non-derivative or derivative security | 938 | $2.23 |
| Apr 01, 2020 |
Director, CEO & President
|
Director, CEO & President | Open market or private sale of non-derivative or derivative security | 2,502 | $2.23 |
| Mar 31, 2020 |
EVP & Chief Financial Officer
|
EVP & Chief Financial Officer | Open market or private sale of non-derivative or derivative security | 4,326 | $2.31 |
| Mar 31, 2020 |
Chief Legal Officer
|
Chief Legal Officer | Open market or private sale of non-derivative or derivative security | 1,786 | $2.31 |
| Mar 31, 2020 |
EVP, COO & CCO
|
EVP, COO & CCO | Open market or private sale of non-derivative or derivative security | 1,854 | $2.31 |
| Mar 31, 2020 |
Director, CEO & President
|
Director, CEO & President | Open market or private sale of non-derivative or derivative security | 4,059 | $2.31 |
| Mar 13, 2020 |
EVP & Chief Financial Officer
|
EVP & Chief Financial Officer | Other acquisition or disposition | -- | -- |
| Mar 13, 2020 |
Chief Medical Officer
|
Chief Medical Officer | Other acquisition or disposition | -- | -- |
| Mar 13, 2020 |
Chief Legal Officer
|
Chief Legal Officer | Other acquisition or disposition | -- | -- |
| Mar 13, 2020 |
EVP, COO & CCO
|
EVP, COO & CCO | Other acquisition or disposition | -- | -- |
| Mar 13, 2020 |
Director, CEO & President
|
Director, CEO & President | Other acquisition or disposition | -- | -- |
| Mar 12, 2020 |
EVP & Chief Financial Officer
|
EVP & Chief Financial Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 163,180 | -- |
| Mar 12, 2020 |
EVP & Chief Financial Officer
|
EVP & Chief Financial Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 260,000 | -- |
| Mar 12, 2020 |
EVP & Chief Financial Officer
|
EVP & Chief Financial Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 225,000 | -- |
| Mar 12, 2020 |
Chief Medical Officer
|
Chief Medical Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 188,285 | -- |
| Mar 12, 2020 |
Chief Medical Officer
|
Chief Medical Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300,000 | -- |
| Mar 12, 2020 |
Chief Medical Officer
|
Chief Medical Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- |
| Mar 12, 2020 |
Chief Legal Officer
|
Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 163,180 | -- |
| Mar 12, 2020 |
Chief Legal Officer
|
Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 260,000 | -- |
| Mar 12, 2020 |
Chief Legal Officer
|
Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 200,000 | -- |
| Mar 12, 2020 |
EVP, COO & CCO
|
EVP, COO & CCO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 188,285 | -- |
| Mar 12, 2020 |
EVP, COO & CCO
|
EVP, COO & CCO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300,000 | -- |
| Mar 12, 2020 |
EVP, COO & CCO
|
EVP, COO & CCO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 375,000 | -- |
| Mar 12, 2020 |
Director, CEO & President
|
Director, CEO & President | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 282,427 | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.